Eli Lilly & Co.

NYSE: LLY
$246.33
+$0.75 (+0.3%)
Closing price December 6, 2021
The FDA has approved Allergan's treatment for migraines in adults. The drug is the first of its class to obtain FDA approval, but the new drug will compete with other recently released treatments for...
Wednesday's top analyst upgrades, downgrades and initiations included Activision Blizzard, Datadog, Delta Air Lines, Eli Lilly, FedEx, Halliburton, Kinder Morgan, Skechers, Teladoc and Waste...
The November 29 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The November 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The October 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The October 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Eli Lilly shares retreated after it released mixed third-quarter financial results before the markets opened on Wednesday.
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Thursday's top analyst upgrades, downgrades and initiations included Abbott Laboratories, CSX, IBM, Netflix, Occidental Petroleum, Whiting Petroleum, Amgen, Gilead Sciences, Merck and Pfizer.
The September 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Eli Lilly announced some good news for people suffering moderate to severe plaque psoriasis when it presented at the 5th Annual Maui Derm NP+PA Fall meeting.
These four top large-cap pharmaceutical stocks for investors to consider all pay solid dividends and look like very solid fourth-quarter ideas.
The September 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The August 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks was mixed.
Eli Lilly shares dipped on Monday after the firm announced results from its midstage clinical trial for the treatment of lung cancer.